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Pseudomyxoma peritonei (PMP, ORPHA26790) is a clinical syndrome characterized by progressive dissemination of
mucinous tumors and mucinous ascites in the abdomen and pelvis. PMP is a rare disease with an estimated
incidence of 1–2 out of a million. Clinically, PMP usually presents with a variety of unspecific signs and symptoms,
including abdominal pain and distention, ascites or even bowel obstruction. It is also diagnosed incidentally at
surgical or non-surgical investigations of the abdominopelvic viscera. PMP is a neoplastic disease originating from a
primary mucinous tumor of the appendix with a distinctive pattern of the peritoneal spread. Computed tomography
and histopathology are the most reliable diagnostic modalities. The differential diagnosis of the disease includes
secondary peritoneal carcinomatoses and some rare peritoneal conditions. Optimal elimination of mucin and the
mucin-secreting tumor comprises the current standard of care for PMP offered in specialized centers as visceral
resections and peritonectomy combined with intraperitoneal chemotherapy. This multidisciplinary approach has
reportedly provided a median survival rate of 16.3 years, a median progression-free survival rate of 8.2 years and
10- and 15-year survival rates of 63% and 59%, respectively. Despite its indolent, bland nature as a neoplasm, PMP
is a debilitating condition that severely impacts quality of life. It tends to be diagnosed at advanced stages and
frequently recurs after treatment. Being ignored in research, however, PMP remains a challenging, enigmatic
entity. Clinicopathological features of the PMP syndrome and its morbid complications closely correspond with
the multifocal distribution of the secreted mucin collections and mucin-secreting implants. Novel strategies are
thus required to facilitate macroscopic, as well as microscopic, elimination of mucin and its source as the key
components of the disease. In this regard, MUC2, MUC5AC and MUC5B have been found as the secreted mucins
of relevance in PMP. Development of mucin-targeted therapies could be a promising avenue for future research
which is addressed in this article.
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With an estimated incidence of 1–2 out of a million [1],
pseudomyxoma peritonei (PMP, ORPHA26790)-also known
as adenomucinosis or gelatinous ascites- is listed as a rare
disease by the NIH Office of Rare Diseases Research
(ORDR) and National Organization for Rare Disorders
(NORD). As an indolent neoplasm with unspecific mani-
festations, PMP tends to be misdiagnosed, or discovered
at advanced stages. Moreover, it is a challenging entity with* Correspondence: david.morris@unsw.edu.au
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unless otherwise stated.debilitating, even fatal complications. Despite a multidis-
ciplinary approach composed of an extensive surgical pro-
cedure and chemotherapy, PMP frequently recurs and
increasingly jeopardizes quality of life. Being ignored in re-
search, however, PMP remains poorly understood and en-
igmatic. This is despite the fact that “rare diseases are rare,
but rare disease patients are numerous” [2] and those with
progressive, life-threatening courses deserve to be further
explored. To enhance outcomes of the conventional ther-
apy, novel approaches based on in-depth understanding of
the pathological processes and biological events in the
pathogenesis of the disease are warranted. Since PMP and
mucin are inextricably linked, any therapeutic interventiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the current knowledge on the crucial role of mucin in the
pathogenesis of the disease is reviewed and a number of
potential therapeutic strategies for mucin elimination in
PMP are addressed.
Definition
PMP is characterized by dissemination of mucinous tumor
implants on peritoneal surfaces and progressive accumula-
tion of mucinous ascites throughout the peritoneal cavity
resulting in the so-called “jelly belly”.
Etiology
Since initial descriptions of PMP as a syndrome in associ-
ation with an ovarian tumor [3] or an appendiceal muco-
cele [4], a pre-existing intraperitoneal mucinous neoplasm
has been implicated as the primary cause of PMP. As
follows, emerging evidence supports the appendiceal ra-
ther than ovarian origin of the disease.
Classification
PMP has been broadly applied to a heterogeneous group
of pathological conditions with a similar clinical presen-
tation, with the site of the primary tumor, neoplastic
phenotype of the peritoneal tumor cells and classifica-
tion of the disease being a matter of controversy. How-
ever, attempts have been made to better define and
classify the condition based on the clinicopathological
characteristics. Ronnett et al. [5] suggested a classifica-
tion of multifocal peritoneal mucinous tumors into three
groups. These include disseminated peritoneal adeno-
mucinosis (DPAM), peritoneal mucinous carcinomatosis
(PMCA) and a third hybrid group called peritoneal mu-
cinous carcinomatosis with intermediate or discordant
features (PMCA I/D), also known as intermediate fea-
tures group (IFG). According to this clinicopathological
classification, DPAM includes histologically benign peri-
toneal lesions associated with ruptured appendiceal mu-
cinous adenomas as well as those with similar pathology
but lacking a demonstrable appendiceal adenoma. Sub-
sequently, Sugarbaker defined PMP as a grade I mucin-
ous adenocarcinoma that arises from an appendiceal
adenoma [6]. Later, they stipulated that the term PMP
should be exclusively used to describe the clinical syn-
drome of mucinous ascites accompanied by a character-
istic distribution of peritoneal mucinous tumors with
the pathologic features of DPAM [7]. Further studies
strongly supported the notion that PMP is a generally
low-grade, indolent neoplasm of appendiceal origin with
rare distant metastases and unlikely involvement of solid
organs [1,8,9]. Since neither adenoma nor adenocarcin-
oma precisely represents the neoplastic nature of PMP,
“mucinous neoplasm of low malignant potential” and
“low-grade appendiceal mucinous neoplasm” have beenproposed in the literature as the alternative terms for
pathological description of the PMP tumor [10].
Pathogenesis
The pathological process starts with neoplastic transform-
ation of the appendiceal goblet cells and subsequent forma-
tion of a primary mucinous tumor. While proliferating,
tumor cells maintain their constitutive level of mucin expres-
sion. As a result, the overall secretion of mucin dramatically
rises [8]. This is followed by intraluminal accumulation of
mucin and eventual development of an appendiceal muco-
cele. A small perforation or rupture of the mucocele is the
key event towards the development of PMP through which
tumor cells gain access into the peritoneal cavity. Lacking cell
surface adhesion molecules, the exfoliated tumor cells pas-
sively circulate with the peritoneal fluid and redistribute
throughout the peritoneal cavity. As a result, tumor implants
and mucin collections form at the peritoneal fluid reabsorp-
tion sites as well as within the dependent portions of the
peritoneal cavity to create PMP’s characteristic pattern of
the peritoneal dissemination (Figure 1) [11]. Accumulating
mucin increases intraabdominal pressure and compresses
visceral organs. Furthermore, extensive involvement of the
peritoneal surface promotes variable inflammatory and fi-
brotic responses in the peritoneal environment and hence
the development of bowel obstruction as a fatal complication
of the disease [12,13]. The detailed role of mucin in the
pathogenesis of PMP will be discussed later.
Clinical presentation
The disease is usually diagnosed after the age of 40 [14],
with an average age at diagnosis of 53 [15]. PMP clinically
presents with a variety of unspecific and sometimes
uncommon signs and symptoms. PMP’s clinical manifes-
tations can be roughly classified based on the disease pro-
gression (Table 1) [16]. In advanced disease, increased
abdominal girth and complaints of abdominal pain related
to intestinal obstruction are the most presenting symptom
seen in 30-50% of the PMP patients as a result of dissemi-
nated mucinous tumor and ascites classically presenting
at laparotomy with jelly belly. In less advanced disease,
local symptoms are seen in 50-80% of PMP patients with-
out jelly belly ascites and might correspond to the site
of the primary tumor, such as appendicitis-like symptoms
in 25% of cases, or the location of the peritoneal implants,
including lower abdominal pain, pelvic pressure and
gynecological complaints in females due to the ovarian
deposits of the mucinous tumor in 20-30% of the patients
[17,18]. Finally, PMP is coincidentally found in up to
20% of patients undergoing such procedures as laparot-
omy, laparoscopy or imaging for other medical conditions,
e.g. hernia [17-27], bladder tumor [28], jelly like material
in urine [29], total uterovaginal prolapse [30], recurrent
rectal cancer [31], pregnancy [32] and cesarean section
Figure 1 Schematic representation of the events resulting in the development of PMP. The pathologic process starts with a neoplastic
transformation of the appendiceal goblet cells and development of a primary mucinous tumor (1). Overproduction of mucin and obstruction of
the appendiceal lumen lead to the development, and subsequent rupture, of a mucocele (2). Shredded tumor cells gain access to the peritoneal
cavity and circulate with the peritoneal fluid (3). Accordingly, tumor cells redistribute and accumulate within the dependent portions of the
peritoneal cavity (3*, downward arrows) as well as at the peritoneal fluid reabsorption sites (3**, upward arrows).
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on the right flank [34] or a subcutaneous nontender um-
bilical nodule [35] have also been reported.
Diagnosis
Imaging
- Ultrasound and parallel fine needle biopsy. Ultrasound
is accessible and inexpensive. However, conclusionsTable 1 Common presentations or incidental discovery of PM














aorticcannot be drawn from ultrasound alone since the mu-
cinous ascites resembles free intraperitoneal fluid [36].
Although cytological investigation of the mucin collec-
tions seems to be a useful accompanying procedure,
sampling errors, dry taps and false negative results due
to low amount of mucin and/or low cellular density are
considered as the disadvantages of parallel fine needle
biopsy [16].P on the basis of the disease progression
nting or incidentally diagnosed with
minal distension, ascites, obstruction [18,36]
minal pain [18] Appendicitis-like syndrome
Presumed cholecystitis
Vague non-specific pain






Abnormal Pap test [18]
s [18] Deep vein thrombosis, rectal bleeding, anaemia
a repair, fibroids, colon cancer, tubal ligation, nephrectomy, abdominal
aneurysm repair
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remains the most widely used imaging modality in PMP.
Higher densities of mucinous ascites compared to the
nonmucinous collections [40], characteristic pattern of
the mucinous accumulation [41] and the extent of the
disease for preoperative planning and prognostic pur-
poses [36] can be evaluated by CT.
- Other imaging methods. Magnetic resonance imaging
(MRI) has been described to show the location of muco-
cele and its morphologic criteria identically to CT. T1-
and T2-weighted MRI are more sensitive in distinguish-
ing between mucin and fluid ascites [42-44]. Although
positron emission tomography (PET) has been suggested
for predicting the peritoneal dissemination [45] and pre-
operative evaluation of pathological grade and potential
for complete cytoreduction [46], its value in PMP re-
mains controversial [47,48].
Circulating tumor markers
Although relatively non-specific [14], the following tumor
markers have been reported to be of value in PMP:
- Carcinoembryonic antigen (CEA). This tumor marker
has been shown to serve as a valuable diagnostic [49]
and prognostic tool [49,50] in the management of PMP.
- Carbohydrate antigen 19.9 (CA19.9). Practical value
of CA19.9 in diagnostic [49] and prognostic [49,51-54]
evaluation of PMP has been reported.
- Carbohydrate antigen 125 (CA125) also known as
MUC16. Although suggested as a marker with diagnostic
sensitivity for PMP [52], CA125 is not widely used as a
tumor marker for PMP. Instead, as a gynecological tumor
marker, it is recommended for exclusion of an ovarian
neoplasm [16].
These tumor markers are also used as a baseline value for
postoperative follow-up. Moreover, they have been reported
as predictors of the completeness of cytoreductive surgery
(CRS) [50,52,53,55], a significant prognostic factor for PMP.
Histopathological analysis
Apart from the characteristic feature of PMP as acellular
to paucicellular mucin pools with variable amounts of
neoplastic mucinous epithelium, immunohistochemical
markers can help to identify the organ of origin. These in-
clude positive cytokeratin 20 (CK20), CEA, caudal-type
homeobox protein 2 (CDX-2), and MUC2 as well as nega-
tive cytokeratin 7 (CK7) and CA125 [16]. Of particular
interest is the secreted mucin MUC2 that is extensively
positive in the patients. Although MUC2 has been sug-
gested as a biological marker of PMP [56-60], its signifi-
cance as a prognostic factor is a matter of controversy [61].
Differential diagnosis
The main entity to be considered in the differential diag-
nosis of PMP is peritoneal mucinous carcinomatosisarising from a primary mucinous carcinoma. Other differ-
ential diagnoses reported in the literature include endo-
metriosis with myxoid change [62], melioidosis (a lethal
infectious disease caused by Burkholderia pseudomallei)
[63] and those with abdominal CT resemblance, e.g. ex-
tensive abdominal plexiform neurofibromatosis [64].
Treatment
Traditional treatment consists of repetitive surgical debulk-
ing. Due to the presence of tumor deposits after the first
debulking surgery, this approach could results in short term
palliation with imminent recurrence or progression, hence
redo procedures and a shorter 5- to 10-year overall survival
(OS) rate of approximately 50% [65-67]. A more aggressive
approach by Sugarbaker [68,69] utilizes peritonectomy and
visceral resections, called cytoreductive surgery (CRS), in
combination with hyperthermic intraperitoneal chemother-
apy (HIPEC) that is featured by direct targeting of the
microscopic disease, locoregional drug availability, minimal
systemic exposure and improved drug penetration through
hyperthermia. This strategy comprises the current standard
of care for PMP with known benefits well-documented
by us [15,53,54,70-81] and others [82-92]. Other proposed
modalities include laparoscopy for less advanced disease
[93,94], whole abdominopelvic radiotherapy (WAPRT) as
a palliative treatment [95] and use of mucolytic [96-100],
antibacterial [58,101,102] and anti-inflammatory [103]
agents with potential values as complementary/adjuvant
therapies.
Prognosis
Although PMP as a neoplastic disease runs a chronic, in-
dolent course with late invasion and only rare metastasis
outside the peritoneum, it is a morbid, recurrent condition
with life-threatening complications. Biological features of
the tumor [61,104] and access to the current standard of
care at specialized oncology centers with a peritoneal sur-
face malignancy program [105-110] comprise the most
important prognostic determinants of PMP. Through a
retrospective, multi-institutional study on 2298 patients
treated at 16 specialized centers affiliated with the Periton-
eal Surface Oncology Group International [15], Chua et al.
reported a median survival rate of 196 months (16.3 years)
and a median progression-free survival rate of 98 months
(8.2 years) as well as 10- and 15-year survival rates of 63%
and 59%, respectively.
Mucin: from intestinal physiology to PMP
Mucin family
Mucins are a diverse family of high molecular weight,
heavily glycosylated proteins (Table 2). Also known as
MUC glycoproteins, mucins are differentially expressed by
specialized epithelial cells of mucosal surfaces throughout
the body in a relatively organ- and cell type-specific
Table 2 Classification, designation and distribution of mucin family
Type of mucin Designation Site of expression
Membrane-associated MUC1 Almost all glandular epithelial surfaces of respiratory, gastrointestinal and female reproductive tracts,
middle ear, salivary gland, mammary gland and normal pancreatic intralobular ducts
MUC3A Gastrointestinal tract epithelium
MUC3B Gastrointestinal tract epithelium
MUC4 Respiratory tract, salivary glands, stomach, colon, eye, vagina, ectocervix, uterus and prostate
MUC11 Gastrointestinal, respiratory, reproductive and urinary tracts, liver and thymus
MUC12 Colon, stomach, pancreas, prostate and uterus
MUC13 Gastrointestinal and respiratory tracts, middle ear and kidney
MUC15 Placenta, salivary gland, thyroid gland, trachea, esophagus, kidney and testis
MUC16 Ocular surface, respiratory and female reproductive tracts and middle ear
MUC17 Gastrointestinal tract, fetal kidney and conjuctival epithelium
MUC20 Kidney, placenta, lung, prostate, liver, colon, esophagus, rectum and middle ear
MUC21 Respiratory tract, thymus, colon and testis
Secreted Gel-forming MUC2 Goblet cells of small intestine and colon
MUC5AC Tracheobronchial goblet cells, gastric epithelial cells, conjunctiva and lacrimal glands
MUC5B Salivary glands, tracheobronchial and esophageal epithelia, pancreatobiliary and endocervical epithelia
MUC6 Gastric mucosa, duodenal Brunner’s glands, hepatobiliary tract, pancreatic centroacinar cells and duct,
basal endometrial and endocervical glands
Non-gel-forming MUC19 Salivary glands, submucosal gland of the tracheal tissue, corneal and conjunctival epithelia and lacrimal
gland tissue
MUC7 Epithelium of the oral cavity, minor salivary gland, respiratory tract, submucosal glands of the bronchus,
conjunctivae and pancreas
MUC8 Normal Human Nasal epithelial (NHNE) cells and middle ear epithelium
MUC9 Fallopian tubes (non-ciliated oviductal epithelial cells)
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sociated and secreted types, with the latter being divided
to gel-forming and non-gel-forming subtypes [112,113].
Membrane-associated mucins communicate information
about extracellular conditions, mediate intracellular signal
transduction, and contribute to morphological and behav-
ioral characteristics of the epithelial cells [114,115].
Secreted mucins provide a physical barrier for epithe-
lial cells lining the respiratory and gastrointestinal tracts
and form the ductal surfaces of such organs as liver,
breast, pancreas and kidney [116]. Moreover, they are
part of a defensive system at the mucosal surfaces, in-
cluding intestinal mucosa.
Mucin in intestinal physiology
While facilitating the transit of intestinal contents [117],
secreted mucins participate in the front line of the enteric
host defense generated by the alliance of the epithelial
cells, immune cells and resident microbiota [118]. This
interactive ecosystem is essential for the maintenance of
intestinal homeostasis and the normal function and activ-
ity of digestive system [119]. The gastrointestinal epithe-
lium and the overlying mucus layer also function as abarrier against intestinal luminal hazards [120]. Colonic
mucus is composed of two layers. The outer, loose layer is
the habitat of the microbial flora. The inner, dense layer is
bacteria-free and firmly attached to the epithelium. This
organization keeps the flora well separated from the mu-
cosal surface. The gel-forming mucin MUC2, which is
specifically secreted in the small intestine and colon, com-
prises the substantial component of this double-layered
mucus compartment (Figure 2). MUC2 of the inner layer
is uncleaved. To form the outer layer, however, MUC2
undergoes proteolytic cleavage to allow expansion of the
polymeric structure [121].
Mucin in PMP
Under normal conditions, metabolic turnover of intes-
tinal mucin is maintained by the constitutive expression
against enzymatic degradation, and, elimination. In PMP,
however, mucin is ectopically secreted and increasingly
deposited in the peritoneal cavity where it is unable to
degrade or drain away. Accumulating mucin causes a
major part of the morbidity in PMP. The typical syn-
drome develops after secreted mucin forms voluminous
gels over months and years. Mucin also plays a key role
Figure 2 MUC2 in colonic mucosa. A Synthesis, secretion and organization of colonic mucosa. The first stage in the biosynthesis of MUC2
is the formation of MUC2 monomer as an N-glycosylated apoprotein in the endoplasmic reticulum. Subsequently, MUC2 dimers are formed
when intermolecular disulfide bonds bridge between the C-terminal cysteine knot domains. During transit through the Golgi apparatus, MUC2
dimers become heavily O-glycosylated. Complete glycosylation of the dimers occurs in Golgi where trimerization through disulfide bonds at the
N-terminus forms protease-resistant trimers. The fully glycosylated and processed MUC2 is densely packed and stored in secretory granules/
vesicles and released through constitutive or stimulated secretory mechanisms. Once released, MUC2 is organized into the firmly adherent inner
layer. At a certain distance from the epithelium, this layer is converted into the loose outer layer through proteolytic cleavage and expansion.
Mucus also contains immunoglobulins and other proteins. B MUC2 structure. The protein core consists of five different regions. Segment (a)
and (b) are two central repetitive regions rich in potential O-glycosylation sites, to which branched carbohydrate chains of 4–12 sugars are
O-glycosidically linked to form a closely packed sheath around the central protein core. Segment (a), also known as VNTR domain, is a large
domain that contains 50–100 “variable number of tandem repeats (VNTRs)” of 23 amino acids, in particular, threonine. Segment (b), also called
PTS domain, is a 347 amino acid domain, containing irregular repeats rich in proline, threonine and serine (PTS). These two segments are linked
together by segment (c) which is a 148 amino acid, cysteine containing region. Segments (d) and (e) are extensive peptide chains rich in cysteine
located at the C and N terminal ends, respectively, containing D domains with sequence homology to von Willebrand factor. These regions are
the presumed sites for end to end polymerization of mucin subunits.
Amini et al. Orphanet Journal of Rare Diseases 2014, 9:71 Page 6 of 12
http://www.ojrd.com/content/9/1/71
Amini et al. Orphanet Journal of Rare Diseases 2014, 9:71 Page 7 of 12
http://www.ojrd.com/content/9/1/71in the biology of the PMP tumor. Most of the tumor
cells are surrounded by a mucin coat that allows them
to freely move, disseminate and “redistribute” within the
peritoneal cavity to create the distinctive feature of PMP.
This coating also seems to act as a protective shield
against immune recognition and chemotherapy. MUC2,
MUC5AC and MUC5B are the gel-forming mucins re-
portedly found in the PMP secretions. The intestinal
mucin MUC2 is known as the PMP-specific mucin. Ac-
cording to O’Connell et al. [8,56], primary ovarian mucin-
ous tumors essentially express MUC5AC whereas solitary
appendiceal mucinous tumors and different categories of
PMP express MUC2 along with MUC5AC. This finding
also supports the notion that PMP is a neoplasm of appen-
diceal origin. In their studies, O’Connell et al. also showed
that MUC2 is behind the high degree of gelation formed in
PMP. Since MUC2 is more extensively glycosylated, it is
more voluminous than MUC5AC on an equimolar basis,
hence formation of abundant mucinous collections where
the average mucin:cell ratio is higher than 10:1. Taken to-
gether, the investigators concluded that PMP is a disease of
the MUC2-secreting goblet cells and that MUC2 could
serve as a molecular marker for PMP [8,56]. Since the ex-
pression level of MUC2 in PMP is seemingly independent
of the degree of the malignant transformation, prognostic
significance of MUC2 is controversial [61].
In two case studies, Mall et al. reported the presence
of MUC5B, in addition to MUC2 and MUC5AC, in
the PMP material [122,123]. Based on the investiga-
tions by Sheehan et al. implicating a low-charge glyco-
form of MUC5B in the production of a tenacious
respiratory mucus plug [124,125], Mall et al. specu-
lated that it may be MUC5B that is responsible for the
semisolid material found in some PMP patients. Given
the high protein content of the PMP secretions, they
also raised the possibility that interactions between
mucin and non-mucin proteins could contribute to the
viscous nature of the PMP exudates [122,123]. Table 3
summarizes a number of studies in which disease-
specific expression pattern of MUC2 and other mucins
in PMP has been explored.
Mucin elimination in the management of PMP
Mucin comprises the cornerstone of the PMP patho-
genesis. However, optimal removal of mucin and mu-
cinous implants via conventional therapies remains
challenging, with the residual disease accounting for
the recurrence of the condition. In order to enhance
the current standard of care, novel strategies are required
to more effectively eliminate mucin and its source. As
such, some efforts have been made to disrupt PMP pro-
duction of MUC2. In this regard, targeting biological
mechanisms regulating the mucin synthesis at tran-
scriptional and post-transcriptional levels could be ofpotential value. Since MAPK pathway has been implicated
in the pathological induction of MUC2 by Pseudomonas
aeruginosa infection [131] and mucoepidermoid carcino-
genesis [132], targeted inhibition of MAPK might be of
therapeutic benefit in PMP. On the basis of the cross-talk
between MAPK and other inflammation-associated signal-
ing pathways [133], multi-targeted agents may be more
effective in PMP where the disease develops within an
inflammatory milieu [134].
In addition, PMP inflammatory microenvironment with
a unique profile of cytokines [13] contributes to the mucin
overproduction. Cytokines reportedly upregulate the ex-
pression of MUC2 and enhance the mucin secretion
[135-137]. Glucocorticoids, on the other hand, have been
shown to downregulate MUC2 via direct inhibition of
glucocorticoid response elements (GREs) and indirect
transrepression of inflammation-associated transcription
factors [138,139]. Choudry et al. recently demonstrated
dexamethasone- and celecoxib-induced inhibition of the
mucin production in a mucin-secreting cancer cell line
with goblet cell phenotype as well as in a murine model of
PMP [103]. Methylation of the MUC2 promoter has also
been suggested as a potential tool for manipulating the ex-
pression of MUC2. Okudaira et al. showed that colorectal
cancer (CRC) cell lines of mucinous type exhibit low-level
methylation at the MUC2 promoter as compared to non-
mucinous cell lines. They concluded that low methylation
status of the MUC2 gene plays a predominant role in the
high level MUC2 expression in mucinous CRC [140].
Through inhibiting the MUC2 promoter methylation,
the Sp-family of transcription factors augments MUC2
expression. Thus, mithramycin, a Sp1 binding site in-
hibitor, effectively blocks the MUC2 expression in colo-
rectal cancer [132,141].
Breakdown of mucin as well as enhancement of cytor-
eduction through locoregional therapies outlines our
intended approach to this challenge. In this regard, we
aim to develop a novel treatment for facilitated, en-
hanced removal of the mucin-tumor burden at both
macroscopic and microscopic levels. For this purpose, a
panel of mucin-secreting cancer cells of gastrointestinal
and peritoneal origin and animal models of PMP [142]
and peritoneal carcinomatosis [143] are employed in our
preclinical investigations. Among a number of mucolytic
agents studied [99,100], bromelain and N-acetyl cysteine
(NAC), two generally-safe mucolytics of plant sources
[144,145], have shown promise. Our preliminary results
indicate bromelain- [146-148] and NAC-induced inhib-
ition of the growth and proliferation of the mucin-
producing cancer cells in vitro, with the cytotoxicity be-
ing augmented when the two are used in combination
(unpublished data). We have also observed the ability of
these mucolytics in dissolving both the mucin samples
from PMP patients ex vivo and the mucin implants in a
Table 3 Some studies exploring the expression of MUC2 against other mucins in PMP (2002–2012)
Study Year Number of PMP cases Percentage of cases exhibiting the expression of mucins
MUC2 Other forms of mucins
O’Connell et al. [8] 2002 100 98% MUC5AC 95%
O’Connell et al. [56] 2002 25 96% MUC5AC 92%
Mohamed et al. [126] 2004 33 97% MUC1 57.5%
Kinkor et al. [127]* 2005 3 ? -
Nonaka et al. [128] 2006 42 100% MUC5AC 100%
Mall et al. [122] 2007 1 100% MUC5AC 100%
MUC5B 100%
Ferreira et al. [129] 2008 7 100% MUC1 28.6%
MUC5AC 100%
MUC6 28.6%
Semino-Mora et al. [58]** 2008 16 N/A‡ N/A‡‡
Baratti et al. [61]*** 2009 85 100% MUC5AC 87.5%
Flatmark et al. [59] 2010 5 100% MUC1 0%
MUC5AC 40%
MUC4 100%
Guo et al. [60] 2011 35 94.3% MUC1 0%





Chang et al. [130]**** 2012 4 64%† MUC5AC 43%††
*Full-text article, in Czech, not accessible. Results of IHC study not available.
**This study reports the expression of MUC2 and MUC5A as the volumetric density of apomucin (Vvi/104 μm) in such compartments of DPAM and PMCA tissues
as epithelium, lymphoid aggregates, stroma vessels and free mucin, respectively, as follows:
‡MUC2: in DPAM: 264 ± 60, 47 ± 16, 31 ± 14 and 261 ± 51; in PMCA: 356 ± 90, 170 ± 26, 117 ± 25 and 1043 ± 282.
‡‡MUC5AC: in DPAM: 90 ± 13, 345 ± 20, 65 ± 17, 37 ± 6; in PMCA: 56 ± 12, 246 ± 17, 50 ± 15 and 48 ± 9.
***The percentages shown for this study are numerical estimations of data originally presented in a column graph.
****In this study, among a total of 14 patients with mucinous adenocarcinoma, 4 cases have reportedly exhibited PMP syndrome. Results of the expression of
MUC2 and MUC5AC, however, are reported in total, with no data individually available regarding the PMP cases.
†, ††Data shown is the percentage of MUC2/MUC5AC expression in all patients with mucinous adenocarcinoma, including PMP ones.
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related toxicity in rats [149]. We are currently perform-
ing final preclinical testing of our mucolytic compound
before proceeding to the clinical phase.
Conclusion
Despite its morbid, debilitating nature with severe
impact on quality of life, PMP remains orphan and
enigmatic. Essential for physiological function of the
gastrointestinal tract, mucin is the major contributor to
the pathophysiology of PMP. Peritoneal implantation of
the tumor cells originating from an appendiceal mucin-
ous tumor results in the progressive accumulation of
ectopic mucin. Given the clinicopathological profile
of the disease compatible with an indolent, generally
low grade malignancy, multifocal collections of voluminousmucin and the ensuing complications are the main de-
terminants of the disease prognosis. As the predomin-
ant, gel-forming mucin secreted in PMP, MUC2 is
responsible for the high degree of gelation and the
characteristic feature of the clinical syndrome. Despite
the current standard of care as extensive surgical resec-
tion combined with chemotherapy, PMP frequently re-
curs; with treatmen options being limited at recurrence.
On this basis, in-depth investigations are warranted
to illuminate unknown aspects of the disease and to
seek novel therapeutic approaches for an enhanced
treatment. Owing to the substantial role of mucin in
the pathogenesis of PMP, development of strategies for
targeting mucin and its biology seems to be of particu-
lar significance that needs to be further explored in
future studies.
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